Home page

The DREAM trial was designed to determine whether ramipril or rosiglitazone can reduce the risk of new onset type 2 diabetes in subjects with impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG).

The study is co-ordinated by the Canadian Cardiovascular Collaboration (CCC) at McMaster University, Hamilton, Canada, and the Diabetes Trials Unit (DTU) at the Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, UK.

News

EuroDREAM Project Office, Diabetes Trials Unit, OCDEM, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LJ
Tel: +44 (0)1865 857257     Fax: +44 (0)1865 857241     Email: dtu@dtu.ox.ac.uk

Home | Freedom of Information | Privacy Policy | Copyright | Accessibility | OCDEM | NDM | Oxford University